News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
12,982 Results
Type
Article (727)
Company Profile (19)
Press Release (12236)
Section
Business (4468)
Career Advice (16)
Deals (650)
Drug Delivery (2)
Drug Development (2327)
Employer Resources (2)
FDA (203)
Job Trends (271)
News (7189)
Policy (376)
Tag
2024 Bio NC Standard (1)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
Academia (37)
Adcomms (3)
Allergies (4)
Alliances (1206)
ALS (1)
Alzheimer's disease (10)
Antibody-drug conjugate (ADC) (8)
Approvals (201)
Artificial intelligence (3)
Bankruptcy (4)
Best Places to Work (218)
BIOSECURE Act (4)
Biosimilars (1)
Biotechnology (15)
Cancer (53)
Cardiovascular disease (5)
Career advice (10)
CAR-T (9)
Cell therapy (27)
Clinical research (1773)
Collaboration (28)
Compensation (14)
COVID-19 (102)
CRISPR (4)
C-suite (9)
Cystic fibrosis (1)
Data (44)
Diabetes (2)
Diagnostics (30)
Drug discovery (1)
Earnings (1395)
Editorial (1)
Employer resources (2)
Events (2380)
Executive appointments (31)
FDA (228)
Featured Employer (2)
Funding (26)
Gene editing (8)
Gene therapy (17)
GLP-1 (17)
Government (43)
Guidances (1)
Healthcare (384)
Infectious disease (103)
Inflammatory bowel disease (6)
Intellectual property (3)
Interviews (3)
IPO (358)
Job creations (61)
Job search strategy (10)
Kidney cancer (1)
Labor market (2)
Layoffs (12)
Legal (64)
Liver cancer (1)
Lung cancer (6)
Lymphoma (10)
Management (1)
Manufacturing (8)
Medical device (63)
Medtech (63)
Mergers & acquisitions (305)
Metabolic disorders (5)
Neurodegenerative disease (4)
Neuroscience (17)
NextGen: Class of 2025 (138)
Non-profit (19)
Northern California (94)
Now hiring (1)
Obesity (3)
Opinion (1)
Ovarian cancer (1)
Pain (6)
Pancreatic cancer (1)
Parkinson's disease (2)
Patents (9)
Patient recruitment (3)
People (1669)
Phase I (800)
Phase II (865)
Phase III (521)
Pipeline (21)
Policy (6)
Postmarket research (25)
Preclinical (269)
Press Release (1)
Prostate cancer (2)
Radiopharmaceuticals (2)
Rare diseases (7)
Real estate (112)
Recruiting (1)
Regulatory (315)
Reports (2)
Research institute (62)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (8)
Series B (2)
Service/supplier (1)
Southern California (88)
Special edition (1)
Spinal muscular atrophy (1)
Sponsored (1)
Startups (103)
Supply chain (1)
United States (584)
Vaccines (11)
Webinars (1)
Weight loss (1)
Date
Today (5)
Last 7 days (20)
Last 30 days (61)
Last 365 days (975)
2025 (214)
2024 (1024)
2023 (1261)
2022 (1594)
2021 (1624)
2020 (1242)
2019 (731)
2018 (540)
2017 (661)
2016 (546)
2015 (591)
2014 (397)
2013 (339)
2012 (292)
2011 (296)
2010 (310)
Location
Africa (14)
Asia (1060)
Australia (89)
California (248)
Canada (68)
China (18)
Colorado (2)
Connecticut (7)
Delaware (5)
Europe (1256)
Florida (16)
Idaho (1)
Illinois (5)
India (1)
Indiana (1)
Japan (2)
Maryland (46)
Massachusetts (106)
Michigan (1)
Minnesota (4)
New Jersey (44)
New Mexico (1)
New York (21)
North Carolina (14)
Northern California (94)
Oklahoma (1)
Pennsylvania (42)
South America (9)
Southern California (88)
Texas (19)
Utah (1)
Washington D.C. (2)
Washington State (9)
Wisconsin (1)
12,982 Results for "calidi biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
March 10, 2025
·
5 min read
Press Releases
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
March 27, 2025
·
6 min read
Biotech Beach
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
June 10, 2024
·
6 min read
Press Releases
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 30, 2025
·
3 min read
Press Releases
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 13, 2025
·
4 min read
Press Releases
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
January 10, 2025
·
4 min read
Press Releases
Calidi Biotherapeutics Announces Proposed Public Offering
November 14, 2024
·
4 min read
Press Releases
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
February 24, 2025
·
5 min read
Business
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
Calidi Biotherapeutics, Inc. today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024.
June 27, 2024
·
4 min read
Business
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights.
May 14, 2024
·
8 min read
1 of 1,299
Next
